More Alzheimer's drugs head for FDA review: what scientists are watching

Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen's aducanumab.

Automated summary

Pharmaceutical companies are submitting their anti-amyloid drug candidates for approval, but concerns remain over the controversial precedent set by Biogen's aducanumab.